Abstract Primary steroid-resistant nephrotic syndrome (SRNS) is characterized by childhood onset of proteinuria and progression to end-stage renal disease. In 26% of cases it is caused by recessive mutations in NPHS2 (podocin). Congenital nephrotic syndrome (CNS) is caused by mutations in NPHS1 (nephrin) or NPHS2. In three families mutations in NPHS1 and NPHS2 had been reported to occur together, and these tri-allelic mutations were implicated in genotype/phenotype correlations. To further test the hypothesis of tri-allelism, we examined a group of 62 unrelated patients for NPHS1 mutations, who were previously shown to have NPHS2 mutations; 15 of 62 patients had CNS. In addition, 12 CNS patients without NPHS2 mutation were examined for NPHS1 mutations. Mutational analysis yielded three different groups. (11 with CNS), no NPHS1 mutation was detected, except for 1 patient, who had one NPHS1 mutation only. This patient was indistinguishable clinically and did not have CNS. (2) In 14 patients with one NPHS2 mutation only (4 with CNS), we detected two additional recessive NPHS1 mutations in the 4 patients with CNS. They all carried the R229Q variant of NPHS2. The CNS phenotype may be sufficiently explained by the presence of two NPHS1 mutations. (3) In 12 patients without NPHS2 mutation (all with CNS), we detected two recessive NPHS1 mutations in 11 patients, explaining their CNS phenotype. We report ten novel mutations in the nephrin gene. Our data do not suggest any genotype/phenotype correlation in the 5 patients with mutations in both the NPHS1 and the NPHS2 genes.
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Introduction
Nephrin and podocin, the protein products of the NPHS1 and NPHS2 genes, directly interact via their C-terminal domains in a protein-protein interaction pathway that is responsible for maintaining glomerular podocyte foot process integrity and function [1, 2] . The presence of two recessive mutations in the NPHS1 and NPHS2 genes that impair function of these proteins results in altered podocyte structure and function. The glomerular filtration barrier to protein is then defective [3] . The mechanistic consequence (phenotype) is that protein leaks from blood into the urinary space to be lost from the body in the urine, thereby causing the nephrotic syndrome (NS). There has been increasing realization that heterozygous mutations in more than one gene coding for proteins involved in important protein-protein interaction pathways may together impact the phenotype, and therefore affect clinical disease, including age of onset, severity, and outcome [4] . These associated heterozygous mutations might contribute to a genetic modifier effect well recognized to be important in determining the ultimate phenotype. This additional level of genetic complexity is superimposed on already complex factors such as the functional consequence of a mutation.
The range of phenotypes in childhood NS has traditionally been described in relation to age at onset. Additional pathological features derived from renal biopsy are superimposed on this clinical classification. Steroidresistant nephrotic syndrome (SRNS) has been described as childhood onset of proteinuria, rapid progression to end-stage renal disease (ESRD), resistance to standard steroid therapy, and absence of recurrence after renal transplantation [5] . In SRNS about 75% of patients exhibit renal histology of focal segmental glomerulosclerosis (FSGS) and 20% show minimal change nephrotic syndrome (MCNS). Following the identification of the NPHS2 gene encoding podocin (OMIM 604766) [6] , different groups have demonstrated that mutations in the NPHS2 gene represent a frequent rather than a rare cause of SRNS, since they occur in approximately 26% of unrelated patients with SRNS [7, 8] . It has been proposed, based on a very small number of patients [6] , that SRNS patients with two recessive mutations in NPHS2 do not respond to standard steroid treatment. We recently confirmed this hypothesis in 190 patients with SRNS and 124 patients with steroid-sensitive nephrotic syndrome (SSNS). We showed that SRNS patients with two recessive mutations in NPHS2 have a reduced risk for recurrence of FSGS in a renal transplant compared with children without mutations (8% compared with 35%) [8] .
Congenital nephrotic syndrome (CNS) is a clinical syndrome where proteinuria and edema are present before birth and are associated with a large placenta, prematurity, and marked edema at birth [9] . Histology shows a wide variability but fibrotic lesions, focal mesangial cell hyperplasia, tubular atrophy, and dilatation of glomerular capillaries are common features [10, 11] . The most frequent cause of CNS is CNS of the Finnish type (CNF), which is an autosomal recessive disorder with a higher incidence in Finland (1:10,000 births) [12] than in other countries [13] . Recessive mutations in NPHS1, encoding nephrin (OMIM 602716) [14] , are the most frequent cause of CNS (CNF). Of Finnish CNS patients, 94% show one of two mutations: a two-base pair deletion in exon 2 (Fin major) or a nonsense mutation in exon 26 (Fin minor) [14] . An R1160X nonsense mutation was recently found to be a founder mutation in the Maltese population [15] . In other populations no mutation "hot-spots" have been found, and mutations are equally distributed over the NPHS1 gene [16, 17] .
The gene products of the two recessive genes, causing SRNS and CNS, nephrin (encoded by NPHS1) and podocin (encoded by NPHS2), were identified as being important for the function of the glomerular slit membrane of podocyte foot processes, which constitutes the primary molecular sieve of the glomerulus [18] . Data showing evidence of a functional inter-relationship between nephrin and podocin within the podocyte were reported recently [15] by identifying mutations both in NPHS1 and NPHS2 in three families. A di-genic inheritance resulting in a tri-allelic number of mutations was thought to modify the histological phenotype from CNS of the Finnish type (CNF) to congenital FSGS [15] .
We therefore examined a cohort of 74 patients with childhood NS for the NPHS1 and NPHS2 genes to test for the frequency of mutations in more than one of the two genes and relate the findings to the phenotype, if possible.
We performed mutational analysis in the promoter region and all 29 NPHS1 exons in 48 patients (11/48 presented as CNS) in whom we had detected two recessive NPHS2 mutations and in 14 patients (4/14 presented as CNS) in whom we had detected one heterozygous NPHS2 mutation only. We also examined 12 CNS patients without NPHS2 mutation for NPHS1. Our primary goal was to determine (1) whether there was any evidence of NPHS1 mutations in the 63 patients with NPHS2 mu-tations, (2) whether there were any genotype/phenotype correlations of combined NPHS1 and NPHS2 mutations, (3) whether mutations in NPHS1 could fully explain the phenotype seen in patients with CNS and no NPHS2 mutation.
In conclusion, we report ten novel NPHS1 mutations. We found 5 patients with combined mutations in NPHS1 and NPHS2, but absence of evident genotype/phenotype correlations.
Patients and methods

Patients
Blood samples for mutational analysis, clinical data, and informed consent were obtained from patients or their parents (http:// www.renalgenes.org). Genomic DNA was isolated directly from blood samples by standard methods [19] using the QIAamp blood kit (Qiagen, Valencia, Calif., USA). Ethic committee approval was obtained from the ethic commission of the University of Freiburg, Germany and was sought from the University of Michigan, Ann Arbor. The clinical diagnoses of SRNS and/or CNS were established by pediatric nephrologists from different centers of pediatric nephrology according to published criteria [20, 21] . Of the 62 patients with NPHS2 mutations, 46 had received standard steroid treatment and proved resistant, only 5 did not receive steroids. Of these 5 patients, 3 had congenital onset, for the other 2 the reason for not receiving steroids is unknown. For 11 patients no data on the treatment modalities were available, but no patient was reported to be steroid sensitive. Of the 12 CNS patients without NPHS2 mutations, 3 had received standard steroid treatment and proved resistant, in 8 patients no standard steroid treatment was performed, and for 1 patient no data on the treatment modalities were available. Three groups of patients were screened for NPHS1 mutations: patients with two recessive NPHS2 mutations, patients with one heterozygous NPHS2 mutation only, and CNS patients with no NPHS2 mutation. In the third group, 2 patients (F475 II-1 and F1328 II-1) also had one affected sibling. Since these siblings showed a similar phenotype we have not included them in the number calculations for clinical data. Patients of groups I, II, and III with mutations in the NPHS1 gene were divided into subgroup A (group I patients), subgroup B (group II patients), and subgroup C (group III patients) in Table 1 . For clinical evaluation we used a standard questionnaire (http://www.renalgenes.org) as previously described [7] . Characteristic features defining the clinical diagnosis were: age of onset, initial symptoms, histology of the kidney biopsy, progression to ESRD, and renal transplantation ( Table 1) . None of the patients showed significant extrarenal manifestations of other organ systems. CNS was defined as the presentation of NS within the first 2 months of life, because one-quarter of the CNF children presented with edema or abdominal distention at birth, another quarter presented during the 1st week of life, and all untreated patients developed full-blown NS before the age of 3 months [21] . CNF in kidney biopsy usually presents as proximal tubular dilatation and diffuse glomerular mesangial hypercellularity at an early stage. Later biopsies show mesangial hypercellularity and degenerative changes such as fibrotic thickening of the Bowman's capsule and interstitial fibrosis [15, 21, 22] . In the patients with two recessive NPHS1 mutations (Table 1 , subgroup B and subgroup C), consanguinity was known for 8 of 15 (53%). The ethnic background of the patients was central European, Turkish, and Arabic.
Mutational analysis
Mutational analysis for NPHS1 was performed by direct sequencing of the promoter region and of all 29 exons of the NPHS1 gene for one strand. For all 18 amplicons (compromising the promoter region and all 29 exons), the forward primers were used for sequencing as described previously [23, 24] . All mutations were confirmed by sequencing the complementary strand. Known single nucleotide polymorphisms within the primer sequences were avoided (http://genome.ucsc.edu/), because single nucleotide variants within the primer sequence can suppress amplification of one of the two alleles of the amplified product. To rule out polymorphisms, at least 160 chromosomes of 80 healthy control individuals (age and ethnic background similar to the patients screened for mutations in NPHS1) were checked for novel mutations by restriction enzyme digestion and denaturing high-performance liquid chromatography. For sequence evaluation the program SEQUENCHER version 4.1.4 (GeneCode, Ann Arbor, Mich., USA) was used. All patients had undergone previous mutational analysis of podocin [8] and exons 6, 7, 8, and 9 of the WT1 gene (data not shown, Ruf et al., in press). None of the patients in this study showed mutations in exons 6, 7, 8, and 9 of the WT1 gene.
Results
Clinical data and summary of results
The study included 75 unrelated patients with NS. Clinical data are shown in Tables 1 and 2 . Renal biopsy results in patient group I were FSGS 28 of 48 (58%), MCNS 9 of 48 (19%), mesangioproliferative glomerulonephritis 2 of 48 (4%), IgM nephropathy 1 of 48 (2%), Alport nephropathy 1 of 48 (2%), CNF 1 of 48 (2%), and no data or no biopsy performed 6 of 48 (13%) ( Table 2 ). Renal biopsy results in patient group II were FSGS 5 of 14 (36%), MCNS 5 of 14 (36%), diffuse mesangial sclerosis (DMS) 1 of 14 (7%), and no data or no biopsy performed 3 of 14 (21%) ( Table 2 ). Renal biopsy results in patient group III were FSGS 2 of 12 (17%), MCNS 2 of 12 (17%), DMS 1 of 12 (8%), CNF 2 of 12 (17%), and no data or no biopsy performed 5 of 12 (41%) ( Table 2 ). The median age at onset was 2.4 years in patient group I (median 3.3 years after subtracting the 11 CNS patients), 1.3 years in patient group II (median 4.0 years after subtracting the 4 CNS patients), and 0.0 years in patient group III. CNS was diagnosed in 11 of 48 (23%) patients of group I and 4 of 14 (29%) patients of group II; 23 of 48 (48%) patients of group I progressed to ESRD with a median age of 9.3 years; 3 of 14 (21%) patients of group II progressed to ESRD with a median age of 13.0 years; 5 of 12 (42%) patients of group III progressed to ESRD with a median age of 3.4 years ( Table 2) . There were 48 patients with two recessive NPHS2 mutations ( Table 2 , group I), but only 1 of them showed an additional heterozygous NPHS1 mutation (Table 1 , subgroup A). There were 14 patients with one heterozygous NPHS2 mutation only ( Table 2 , group II); 4 of these patients had two additional recessive NPHS1 mutations (Table 1 , subgroup B). Twelve CNS patients showed no NPHS2 mutation (Table 2, group III), but 11 of them had two recessive NPHS1 mutations (Table 1 , subgroup C). Detection of 10 novel and 9 known NPHS1 mutations Since the result of the NPHS2 mutational analysis has been reported previously [8] , we describe here only the results for the NPHS1 mutational analysis. NPHS1 mutational analysis showed 19 different mutations in the NPHS1 gene; 10 were missense mutations, 3 were nonsense mutations, leading to a stop codon, 4 were frameshift mutations, leading to a premature stop codon, and 2 were splice site mutations ( Table 1) . Ten of the mutations have never been described before and are therefore novel. All novel mutations were absent from 160 chromosomes of healthy control individuals. The novel mutations include (Table 1) : (1) a C65T transition leading to a conservative amino acid exchange A22 V (codon conserved in mice) was found homozygously in A140; (2) a C385T transition leading to a conservative amino acid exchange L130F (codon conserved in mice) was found heterozygously in F1328 II-1 and F1328 II-3; (3) a C1135T transition leading to a nonconservative amino acid exchange R379 W (codon conserved in mice and Drosophila melanogaster) was found homozygously in F212; (4) a T1258G transversion leading to a conservative amino acid exchange F420 V (codon conserved in mice) was found heterozygously in F1017; (5) a T1738G transversion leading to a non-conservative amino acid exchange W580G (codon conserved in mice and Drosophila melanogaster) was found heterozygously in F228; (6) a G2014C transversion leading to a conservative amino acid exchange A672P (codon conserved in mice and Drosophila melanogaster) was found homozygously in F1093; (7) a G2971C transversion leading to a conservative amino acid exchange V991L (codon not conserved in evolution) was found heterozygously in F1268; (8) a C2479T transition leading to a premature stop codon (R827X) was found heterozygously in F228; (9) a deletion of C at position 1814 in the 605th codon inducing a frameshift resulting in a stop codon at V621X was found homozygously in F439; (10) an obligatory splice site mutation IVS20+2T!A involving the 5 0 donor splice site of intron 20 was found homozygously in F294.
In 4 patients of three families (F475 II-1, F475 II-2, F435, and F1296) we found homozygously a C2552T transition leading to a conservative amino acid exchange A851 V (codon conserved in mice and Drosophila melanogaster). This mutation was not found in any other patient and was absent from 94 healthy control individuals. It only occurred in combination with the homozygous mutation: deletion TCA, insertion CC at position 2617, leading to a stop codon at position 904 (Table 1) . Both mutations are localized in exon 19, only 65 base pairs apart from each other. In the healthy mother (F475 I-2) both mutations were found heterozygously. Both mutations were first described by Beltcheva et al. [16] , but this publication does not specify if they occur in the same patient. Both mutations were not found in any other patients. The combined appearance of A851V and delTCAinsC2617 is apparently due to linkage disequilibrium. In patient F1017, originally from Germany, we describe the first occurrence of Fin major [delCT121 (A90X)] outside Scandinavia.
Two recessive NPHS2 mutations in combination with single heterozygous NPHS1 mutation In 1 patient with SRNS and two homozygous NPHS2 mutations (F1268), one heterozygous NPHS1 mutation was found (Table 1, subgroup A) . Since the amino acid exchange V991L is conservative and is not conserved in evolution, and since the patient (F1268) is originally from Oman, this mutation might represent a rare innocuous polymorphism not found in the 80 Caucasian healthy control individuals.
Single heterozygous NPHS2 mutation in combination with two recessive NPHS1 mutations In 4 of 14 patients with one heterozygous NPHS2 mutation only, two recessive NPHS1 mutations were found (Table 1, subgroup B). All of these 4 patients had CNS and showed only one heterozygous NPHS2 mutation with the amino acid exchange R229Q. No mutation in NPHS1 was found in 10 of 14 patients of this group.
Two recessive NPHS1 mutations in CNS patients with no NPHS2 mutation In 11 of 12 CNS patients with no NPHS2 mutation, we detected two recessive NPHS1 mutations (Table 1 , subgroup C). These mutations would explain their CNS phenotype.
Single heterozygous mutations detected in NPHS2
The single heterozygous NPHS2 mutations found in 14 patients (Table 2 , group II) were described by Ruf et al. [8] , but because of the importance of combined NPHS1 and NPHS2 mutations, they should be reassessed. In 8 of 14 patients we found the common amino acid exchange R229Q. In 2 of 14 patients we found V290M heterozygously, in 1 of 14 patients we observed R138Q heterozygously and in 1 of 14 patients E310V heterozygously. All 4 occur in compound heterozygous or homozygous mutations in other patients [8] and for R229Q and R138Q clear functional relevance has been demonstrated [25, 26] . There was 1 of 14 patients with the amino acid exchange A242V and 1 of 14 patients Q328R. The significance of these single heterozygous mutations remains unclear.
Discussion
We report ten novel NPHS1 mutations in children with CNS. Only 5 patients with combined mutations in NPHS1 and NPHS2 were identified. We did not observe any obvious genotype/phenotype correlations regarding age at onset and histological presentation.
Koziell et al. [15] first reported mutations both in NPHS1 and NPHS2 in four individuals from three different families with congenital FSGS. One patient showed a homozygous NPHS1 mutation and only one heterozygous NPHS2 mutation (R229Q). Three patients (from two families) showed only one heterozygous NPHS1 mutation and a homozygous NPHS2 mutation. Caridi et al. [27] reported one patient with only one heterozygous NPHS1 mutation and only one heterozygous NPHS2 mutation (R229Q). To further evaluate these hypotheses of a digenic effect for mutations in NPHS1 and NPHS2, we performed mutational analysis of NPHS1 in a cohort of 74 patients in whom we had previously performed analysis of NPHS2 [8] . We describe here 5 patients with a "triallelic hit", 4 patients (F435, F451, F1296, A140) with two recessive NPHS1 mutations and only one heterozygous NPHS2 mutation (Table 1 , subgroup B), and one patient (F1268) with only one heterozygous NPHS1 mutation and two homozygous NPHS2 mutations (Table 1 , subgroup A). In all 4 patients of subgroup B, the single heterozygous mutation in the NPHS2 gene was R229Q. This mutation has previously been described as a polymorphism, since it was found in 3% of all chromosomes in 100 healthy controls [7] . A functional relevance had been claimed for R229Q. The codon is highly conserved in evolution, the amino acid exchange is non-conservative, and it segregated with the disease in certain families. The encoded peptide is altered and the interaction with nephrin in nephrin-binding assays diminished [25] . However, our group and others recently detected R229Q in patients with SRNS, SSNS, and in healthy controls [8, 27] . In this study, in the 4 patients bearing this sequence variant as the third altered allele, the two recessive NPHS1 mutations were sufficient to explain their CNS phenotype. As far as clinical data were available, no significant clinical pleiotropic difference was noticed between these 4 patients and CNS patients with two recessive NPHS1 mutations and absence of NPHS2 mutation (Table 1 , subgroup B and C, respectively).
In F1268 we found only one heterozygous NPHS1 mutation and two homozygous NPHS2 mutations (Table 1, subgroup A). The two homozygous NPHS2 mutations found in this patient have both been previously described [7, 8] : an insertion of T at position 460-467 inducing a frameshift resulting in a stop codon at V165X and a G709C tranversion leading to a conservative amino acid exchange E237Q (Table 1 , subgroup A). To date the second sequence variant has only been found heterozygously by our group in 1 SRNS and 1 SSNS patient [8] . Recently, we detected this sequence variant heterozygously paired in cis with a heterozygous splice site mutation and in trans with a heterozygous deletion in a SRNS patient (Mucha et al., unpublished data). These findings support the suspicion that E237Q might be a rare polymorphism, even though it was absent from 80 healthy controls.
The NPHS1 mutation G2971C that leads to a conservative amino acid exchange V991L was found heterozygously in F1268. This amino acid exchange is conservative and the codon is not conserved in evolution. We could not find this mutation in 196 chromosomes of 98 healthy control individuals. However, since this family is from the Arab country of Oman, it might still represent a rare polymorphism in the Arab population, not detected in healthy controls from central Europe. Since both the NPHS2 variant E237Q and the NPHS1 variant V991L probably represented innocuous polymorphisms, the patient's phenotype most likely is due to the homozygous NPHS2 mutation V165X (Table 1, subgroup A) . This is consistent with the finding that the clinical data available for this patient are similar to clinical data from patients with two recessive NPHS2 mutations and no NPHS1 mutation ( Table 1 , subgroup A; [8] ): Age at onset was 1.6 years compared with 2.4 years; initial symptoms were acute edema and fever. Steroid therapy was started recently. No biopsy has been performed to date.
Caridi et al. [27] reported one patient with one heterozygous NPHS1 mutation only (amino acid exchange A907T) and R229Q in NPHS2. This patient has an age at onset of proteinuria of 1.4 years, is steroid sensitive, and has FSGS histology. However, the patient's healthy mother showed the same molecular findings.
Koziell et al. [15] reported co-existence of NPHS1 and NPHS2 mutations in four patients from three families. The third mutation was suspected to modify the histological phenotype from CNS of the Finnish type (CNF) to congenital FSGS, which was observed in all 4 patients. We report 5 patients with combined NPHS1 and NPHS2 mutations. Biopsy showed MCNS in 1 of 5 patients, DMS in 1 of 5 patients, and was not performed in 3 of 5 patients (Table 1 , subgroup A and subgroup B). Congenital FSGS was not reported in any of our patients, so we cannot compare these findings.
We further examined another 12 CNS patients without NPHS2 mutation. In 11 of 12 patients two recessive NPHS1 mutations were found (Table 1 , subgroup C), explaining their CNS phenotype. Two patients (F475 and F1328) also had affected siblings and shared the genotype with them. The clinical expression of the disease in these siblings was indistinguishable (Table 1 , subgroup C).
In family F1328 we report 2 affected individuals with compound heterozygous NPHS1 mutations and an unusually mild phenotype for the disease, characterized by absence of ESRD even at 24.0 and 20.0 years of age (Table 1 , subgroup C). The mutations are a heterozygous C385T transition leading to the conservative amino acid exchange L130F, and a heterozygous G1868T transversion leading to the non-conservative amino acid exchange C623F. None of our other patients showed these mutations. L130F is novel; a heterozygous C623F mutation was described previously [23] . Other cases with a mild phenotype have been described with NPHS1 mutations. Remission of proteinuria in cases with characteristic CNF histology has been reported [28] . Koziell et al. [15] described a mild phenotype in Maltese patients with ho-mozygous R1160X, a founder mutation in the Maltese population. Patrakka et al. [22] reported clinical features resulting from different NPHS1 mutations. They describe a milder phenotype in one patient with Fin major and a missense mutation compared with patients with Fin major and/or Fin minor mutations only [22] . F1328 II-1 is a 24-year-old patient with NS from birth. He is steroid resistant and his renal biopsy (obtained at the age of 7.8 years) showed mild FSGS. To date his renal function is normal and he does not need treatment. His sister F1328 II-3, who shares the same genotype, also exhibits a very similar phenotype (NS, normal renal function, no treatment). Her renal histology, however, differs and was without pathological findings at the age of 19.5 years (by light microscopy, immunohistochemistry, and electron microscopy). These findings emphasize that there can be rare cases of unusually mild phenotypes in patients with NPHS1 mutations.
In the group of SRNS patients with two recessive NPHS 2 mutations (Table 2 , group I), 11 of 48 (23%) patients showed CNS. This confirms the finding that CNS, which usually results from recessive mutations in NPHS1, can also result from NPHS2 mutations [8, 15] , and supports the genetic heterogeneity of CNS. The percentage of CNS patients with NPHS2 mutations is still surprisingly high. Within the group of 27 patients with CNS (Table 2 11 patients of group I, 4 patients of group II, and 12 patients of group III), we found in 15 (55%) patients two recessive NPHS1 mutations, and in 11 of 27 (41%) patients two recessive NPHS2 mutations. No mutation was found in 1 of 27 (4%) patients with CNS.
When comparing phenotypes between these two CNS groups (patients with two recessive NPHS1 mutations versus patients with two recessive NPHS2 mutations), we notice especially differences in the biopsy results. Of the CNS patients with two recessive NPHS2 mutations, 7 of 14 (50%) showed FSGS (2/14 MCNS, 1/14 CNF, 1/14 MP, 3/14 not performed) [8] . This confirms the previous findings, since NPHS2 has been described as causative for SRNS with FSGS [6] . Karle et al. [7] found FSGS in 75% of NPHS2 patients. Biopsy findings in the 15 CNS patients with two recessive NPHS1 mutations (Table 1 , subgroup B and subgroup C) were surprisingly diverse: only 2 of 15 results showed the histological picture of CNF [in 1 case the biopsy report could not exclude CNF (F435)]. In 3 of 15 patients the biopsy revealed MCNS, which is unusual for NPHS1 patients. One patient showed mild FSGS, but the biopsy was performed at the age of 7.8 years. DMS was found in 2 of 15 patients. In 5 of 15 patients no biopsy was performed, and in 2 of 15 results were not available. In CNS patients with two recessive NPHS2 mutations, 6 of 14 (43%) developed ESRD at a median age of 6.0 years and all 6 (43%) had kidney transplants at a median age of 7.2 years [8] . In CNS patients with two recessive NPHS1 mutations, 5 of 15 (33%) developed ESRD at a median age of 3.0 years and all 5 (33%) had kidney transplants at a median age of 4.0 years (Table 1 , subgroup B and subgroup C).
In addition to the 19 NPHS1 mutations in Table 1 , we identified in 8 patients the known sequence variant G1223A (R408Q) heterozygously. Lenkkeri et al. [23] considered R408Q a mutation, even though it was found heterozygously in 4 of 30 healthy control individuals, and in a Finnish patient, in addition to 2 other heterozygous mutations. We detected this sequence variant heterozygously in 5 of 49 (10%) patients of group I, 1 of 14 (7%) patients of group II, 2 of 14 (14%) patients of group III (F228, F1017) and 10 of 83 (12%) healthy controls, and therefore consider it an innocuous polymorphism.
In conclusion, in this study we did not find any evidence for di-genic inheritance of NPHS1 and NPHS2 mutations as a "tri-allelic hit" that would result in phenotypic modifications. Compared with previously published data based on a limited number of patients, the frequency of patients carrying combined mutations in NPHS1 and NPHS2 is rather low. We report 4 patients with two recessive NPHS1 mutations in addition to the heterozygous NPHS2 sequence variant R229Q. The phenotype of our 4 patients (Table 1, subgroup B) was not altered by the presence of R229Q. A striking difference in the phenotype of these patients compared with the phenotype of patients with two recessive NPHS1 mutations without NPHS2 mutation could not be observed.
In 1 patient only one heterozygous NPHS1 mutation and two recessive NPHS2 mutations were found (Table 1 , subgroup A), as reported by Koziell et al. [15] for 3 patients from two families. The phenotype in our patient does not differ from other patients with two recessive NPHS2 mutations and without mutation in NPHS1.
A patient with only one heterozygous NPHS1 mutation and only one heterozygous NPHS2 mutation, as described earlier [27] , has not been identified in our study. In the limited number of 5 patients, our data does not suggest that patients with combined mutations in NPHS1 and NPHS2 show any genotype/phenotype correlation.
